New York – September 29, 2026 -- 120/80 Health Group has logged its eighth consecutive year of record growth, fueled by new client wins and deepening relationships across healthcare and life sciences.
Top-10 biopharma and diagnostic firms sign on for AI-driven work
The firm added multiple category-leading clients in 2026 and began working with several top-10 global biopharmaceutical and diagnostic companies applying AI to drug, test and device development. The agency has shifted from brand-awareness communications for early-stage digital health startups to a strategic consultancy serving businesses from pre-Series A through publicly traded companies.
Leadership team expands with four senior appointments
Randi Liodice joins as chief growth officer, tasked with driving client growth. Paula DeGangi has been promoted to chief client officer and managing partner leading AOx3, while Mike Fay becomes Group chief strategy officer and managing partner. Jen Long continues as chief client officer and managing partner at 120/80, also overseeing the financial communications practice.
Company formalizes Group identity and new market position
The business has consolidated under the 120/80 Health Group name, adopting the positioning "The business outcomes partner to healthcare innovators." The 120/80 and AOx3 brands retain distinct teams and client relationships but now share access to the Group's broader technology, strategies and practices. A redesigned website went live to reflect the updated corporate structure and client work.
CEO Rob Cronin said the growth reflects client trust in turning innovation into adoption and enterprise value, framing the company's mission as ensuring no healthcare innovation fails to reach the people who need it.